Safety and efficacy of zoledronic acid in multiple myeloma

The Lancet

Volumn 377, Issue 9784, 2011, Pages 2177-2178

  Kyrgidis, Athanassios ^a   Tzellos, Thrasivoulos George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID;

BONE DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HAZARD RATIO; HUMAN; JAW OSTEONECROSIS; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79959721289     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60958-6     Document Type: Letter

References (4)

1. GJ Morgan, FE Davies, WM Gregory et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 2010 1989 1999
2. A Kyrgidis, E Verrou, K Kitikidou, C Andreadis, E Katodritou, K Vahtsevanos Reply to I. Abraham J Clin Oncol 28 2010 e145 e147
3. A Kyrgidis, S Triaridis Methods and biostatistics: a consise guide for peer reviewers Hippokratia 14 2010 13 22
4. R Weitzman, N Sauter, EF Eriksen et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006 Crit Rev Oncol Hematol 62 2007 148 152 (Pubitemid 46575276)